Accelerated Immuno Chemoradiotherapy Based on FDG-PET/CT for Small Volume in Locally Advanced NSCLC (PACCELIO) – A Phase II Multicenter Randomized Open-Label Trial Protocol - Summary - MDSpire

Accelerated Immuno Chemoradiotherapy Based on FDG-PET/CT for Small Volume in Locally Advanced NSCLC (PACCELIO) – A Phase II Multicenter Randomized Open-Label Trial Protocol

  • By

  • Rami El Shafie

  • Jonas Willmann

  • Eleni Gkika

  • Tanja Schimek-Jasch

  • Matthias Miederer

  • Farastuk Bozorgmehr

  • Frank Griesinger

  • Farkhad Manapov

  • Petros Christopoulos

  • Thomas Hehr

  • Markus Hecht

  • Rebecca Bütof

  • Martin Stuschke

  • Matthias Guckenberger

  • Gerald Schmid-Bindert

  • Jan Meiners

  • Sascha Herzer

  • Sonja Hartmann

  • Joana Lamché

  • Stefan Rieken

  • Ursula Nestle

  • April 17, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy and safety of accelerated immuno chemoradiotherapy using FDG-PET/CT for patients with small volume locally advanced non-small cell lung cancer (NSCLC), focusing on primary endpoints such as progression-free survival and overall survival.

Key Findings:
  • Lung cancer is a leading cause of cancer-related mortality, with NSCLC accounting for 80-90% of cases, and specific statistics on survival rates.
  • Current treatment for unresectable stage III NSCLC involves chemoradiation followed by durvalumab, with data from the PACIFIC trial.
  • Integration of FDG-PET/CT improves target volume definition, potentially enhancing local tumor control, supported by trial data.
  • Hypofractionated radiotherapy schedules may reduce toxicity and improve patient compliance, with evidence from recent studies.
Interpretation:

The study aims to address high attrition rates in treatment by optimizing radiotherapy planning and reducing treatment duration, potentially improving outcomes for patients with stage III NSCLC, particularly through targeted interventions.

Limitations:
  • The study's findings may not be generalizable to all NSCLC patients due to specific inclusion criteria and potential biases in patient selection.
  • Long-term outcomes and survival benefits need further validation in larger cohorts, with a focus on diverse populations.
Conclusion:

The PACCELIO trial seeks to enhance treatment efficacy and reduce toxicity in locally advanced NSCLC through innovative use of imaging and treatment strategies, emphasizing the role of FDG-PET/CT.

Original Source(s)

Accelerated Immuno Chemoradiotherapy Based on FDG-PET/CT for Small Volume in Locally Advanced NSCLC (PACCELIO) – A Phase II Multicenter Randomized Open-Label Trial Protocol

  • by Rami El Shafie, Jonas Willmann, Eleni Gkika, Tanja Schimek-Jasch, Matthias Miederer, Farastuk Bozorgmehr, Frank Griesinger, Farkhad Manapov, Petros Christopoulos, Thomas Hehr, Markus Hecht, Rebecca Bütof, Martin Stuschke, Matthias Guckenberger, Gerald Schmid-Bindert, Jan Meiners, Sascha Herzer, Sonja Hartmann, Joana Lamché, Stefan Rieken, Ursula Nestle

  • April 17, 2026

Related Content

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report